Table 3.
Differences in metabolic and hepatic features after lockdown in the entire cohort according to weight gain.
| Patients without Increased Weight N = 186 |
Patients with Increased Weight N = 171 |
|||||
|---|---|---|---|---|---|---|
| Variable | Before Lockdown | After Lockdown | p Value | Before Lockdown | After Lockdown | p Value |
| Lifestyle | ||||||
| MD, n (%) | 91 (49) | 100 (54) | 0.24 | 94 (55) | 72 (42) | 0.91 |
| PA, n (%) | 65 (35) | 67 (36) | 0.88 | 60 (35) | 43 (25) | 0.02 |
| Metabolic Features | ||||||
| T2DM, n (%) | 41 (22) | 41 (22) | 1.00 | 43 (25) | 43 (25) | 1.00 |
| Hypertension, n (%) | 102 (55) | 106 (57) | 0.08 | 94 (55) | 94 (55) | 1.00 |
| Dislipidemia, n (%) | 97 (52) | 100 (54) | 0.16 | 92 (54) | 96 (56) | 0.05 |
| Glycemia, mg/dL | 106 ± 22 | 104 ± 21 | 0.13 | 106 ± 25 | 112 ± 32 | 0.002 |
| HDL cholesterol mg/dL | 49 ± 13 | 49 ± 13 | 0.94 | 51 ± 14 | 51 ± 15 | 0.22 |
| LDL cholesterol mg/dL | 103 ± 97 | 105 ± 35 | 0.78 | 100 ± 31 | 104 ± 34 | 0.18 |
| Triglycerides mg/dL | 122 (93–164) | 121 (94–151) | 0.07 | 114 (89–160) | 117 (95–162) | 0.40 |
| Liver Disease | ||||||
| Increased ALT, n (%) | 50 (27) | 41 (22) | 0.09 | 36 (21) | 51 (30) | 0.02 |
| Increased AST, n (%) | 19 (10) | 20 (11) | 1.00 | 15 (9) | 20 (12) | 0.16 |
| Increased GGT, n (%) | 63 (34) | 58 (31) | 1.00 | 43 (25) | 60 (35) | 0.01 |
| US steatosis ➢ 0–1, n (%) ➢ 2–3, n (%) |
89 (48) 97 (52) |
81 (44) 105 (56) |
0.21 | 70 (41) 101 (59) |
53 (31) 118 (69) |
0.002 |
| FIB-4 | 1.31 (0.95–1.73) | 1.29 (1.01–1.82) | 0.11 | 1.28 (0.89–1.64) | 1.28 (0.95–1.67) | 0.13 |
| FIB-4 < 1.3, n (%) | 78 (42) | 80 (43) | 1.00 | 77 (45) | 79 (46) | 0.32 |
| FIB-4 > 2.67, n (%) | 6 (3) | 9 (5) | 0.16 | 8 (5) | 8 (5) | 1.00 |
MD, Mediterranean diet. PA, physical activity. T2DM, type 2 diabetes. HDL, high-density lipoprotein. LDL, low-density lipoprotein. ALT, alanine aminotransferase. AST, aspartate aminotransferase. GGT, gamma-glutamyltransferase. US, ultrasound. FIB-4, fibrosis 4 score.